Genetic and functional analysis of the human immunodeficiency virus (HIV) type 1-inhibiting F12-HIVnef allele.
The primary human immunodeficiency virus type 1 (HIV-1) Nef mutant F12-HIVNef is characterized by three rare amino acid substitutions, G(140)E, V(153)L and E(177)G. It was reported previously that the expression of F12-HIVNef in the context of the highly productive NL4-3 HIV-1 strain blocks virus replication at the level of virus assembly and/or release by a mechanism depending on the presence of the CD4 intracytoplasmic tail. Here, it is reported that NL4-3 HIV-1 strains expressing F12-HIVnef alleles that were back-mutated in each amino acid substitution readily replicated in CD4(+) cells. Attempting to correlate possible functional alterations with antiviral effects, both F12-HIVNef and its back mutants were tested in terms of well-characterized markers of Nef expression. Both F12-HIVNef and its G(177)E back mutant did not down-regulate CD4 as the consequence of a greatly reduced rate of CD4 internalization. On the other hand, F12-HIVNef as well as the E(140)G and L(153)V back mutants failed to activate the p62 Nef-associated kinase (p62NAK). Thus, only F12-HIVNef was defective in both accelerated rates of CD4 internalization and p62NAK activation, whereas at least one Nef function was restored in all of the back mutants. Infection of cells expressing Nef-resistant CD4 molecules with HIV-1 strains encoding F12-HIVNef back mutants showed that both the lack of accelerated CD4 endocytosis and an, as yet, still unidentified function are required for the F12-HIVNef inhibitory phenotype. These results provide a detailed functional analysis of the F12-HIVnef allele and support the idea that both CD4 accelerated internalization and p62NAK activation are part of the essential steps in the virus replication cycle.
D'Aloja
Paola
P
University of Erlangen, Department of Dermatology, Erlangen, Germany2.|Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy1.
Santarcangelo
Anna Claudia
AC
Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy1.
Arold
Stefan
S
Department of Biochemistry and Molecular Biology, University College London, London, UK3.
Baur
Andreas
A
University of Erlangen, Department of Dermatology, Erlangen, Germany2.
Federico
Maurizio
M
Laboratory of Virology, Istituto Superiore di Sanità, Viale Regina Elena, 299, 00161 Rome, Italy1.
D000483:Alleles; D019943:Amino Acid Substitution; D015496:CD4-Positive T-Lymphocytes / Q000821:virology; D002460:Cell Line; D004789:Enzyme Activation; D015693:Gene Products, nef / Q000737:chemistry / Q000235:genetics / Q000502:physiology*; D015754:Genes, nef; D015658:HIV Infections / Q000821:virology; D015497:HIV-1 / Q000235:genetics* / Q000472:pathogenicity / Q000502:physiology*; D006801:Humans; D009154:Mutation; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D014779:Virus Replication; D054311:nef Gene Products, Human Immunodeficiency Virus; D054462:p21-Activated Kinases
D015693:Gene Products, nef; D054311:nef Gene Products, Human Immunodeficiency Virus; D017346:Protein Serine-Threonine Kinases; D054462:p21-Activated Kinases